Synthetech acquires peptide resin technology
Synthetech, a US provider of peptide building blocks, chiral intermediates and pharmaceutical derivatives, has acquired the technology assets and customer lists of Colorado Biotechnology Associates, (CBA) for a range of cross-linked and functionalised polymeric resins used widely in Solid Phase Peptide Synthesis (SPPS).
Synthetech, a US provider of peptide building blocks, chiral intermediates and pharmaceutical derivatives, has acquired the technology assets and customer lists of Colorado Biotechnology Associates, (CBA) for a range of cross-linked and functionalised polymeric resins used widely in Solid Phase Peptide Synthesis (SPPS).
Under the arrangement, Dr Rodger Raubach, CBA's founder and principal owner, will transfer proprietary resin knowhow to Oregon-based Synthetech, and serve as a consultant for scale-up, technical support, customer qualification and business development for a period of three years.
The transferred technology includes the procedure to attach the specified terminal amino acid to the resin, a key value-added service to peptide customers. Synthetech plans to produce and have available for distribution resin batches within the next three months.